摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-methylchroman-5-ol | 600176-54-3

中文名称
——
中文别名
——
英文名称
6-methylchroman-5-ol
英文别名
6-methyl-3,4-dihydro-2H-chromen-5-ol
6-methylchroman-5-ol化学式
CAS
600176-54-3
化学式
C10H12O2
mdl
——
分子量
164.204
InChiKey
KKJXTGDMECUASG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-methylchroman-5-olcaesium carbonate 、 sodium bromide 作用下, 以 甲醇乙腈 为溶剂, 生成 methyl 2-(8-cyanothio-6-methylchroman-5-yloxy)acetate
    参考文献:
    名称:
    Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) δ agonists
    摘要:
    A series of 1,4-benzyloxybenzylsulfanylaryl carboxylic acids were prepared and their activities for PPAR receptor subtypes (alpha, beta, and gamma) with potential indications for the treatment of dyslipidemia were investigated. Analog 13a displayed the greatest binding affinity (IC50 = 10 nM) and selectivity (120-fold) for PPAR delta over PPAR alpha. Many of the analogs investigated were found to be highly selective for PPAR delta and were dependent on the point of attachment of the substituent. In the 1,4-series, analog 28e was found to be the most potent (IC50 = 1.7 nM) and selective (> 1000-fold) compound for PPAR delta. None of the compounds tested showed appreciable binding affinity for PPAR gamma. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.046
点击查看最新优质反应信息

文献信息

  • Compounds that modulate PPAR activity and methods of preparation
    申请人:——
    公开号:US20030207916A1
    公开(公告)日:2003-11-06
    This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物,以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。
  • THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY
    申请人:Warner-Lambert Company LLC
    公开号:EP1485091A1
    公开(公告)日:2004-12-15
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    申请人:Gilead Sciences, Inc.
    公开号:EP2220046B1
    公开(公告)日:2014-06-18
  • US6833380B2
    申请人:——
    公开号:US6833380B2
    公开(公告)日:2004-12-21
  • [EN] THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY<br/>[FR] DERIVES DE THIAZOLE ET D'OXAZOLE QUI MODULENT L'ACTIVITE DU RECEPTEUR PPAR
    申请人:WARNER LAMBERT CO
    公开号:WO2003074052A1
    公开(公告)日:2003-09-12
    This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
查看更多